Search results for "Hydrochloride"

showing 10 items of 194 documents

Synthesis and COX inhibition of 7-R1-8-R2-1-ethyl-3,4-dimethyl-, 4,10-dihydro-1H-pyrazolo[3,4-c][1,5]benzodiazocine-5,11-diones

2008

The title compounds were easily synthesized by reacting the 4-aminopyrazole hydrochloride 2 and the substituted 2-nitrobenzoyl chlorides 3a-d. The obtained 2-nitrobenzamides 4a-d were methylated and then reduced to give the corresponding amines 6a-d. These were hydrolyzed then directly converted into 4,10-dihydro-1H-pyrazolo[3,4-c][1,5]benzodiazocine-5,11-diones 1a-d by the action of SOCl2 in benzene. These were tested for their COX inhibitory activity, showing an inhibitory profile against both COX-1 and COX-2, being slightly more selective against COX-2 with a percentage of inhibition, at the concentration of 10 μM, in the range 42.0 – 55.0.

Hydrolysischemistry.chemical_compoundchemistryHydrochlorideOrganic ChemistryPyrazoleCOX inhibitorsPyrazolePyrazole; COX inhibitorsBenzeneSettore CHIM/08 - Chimica FarmaceuticaMedicinal chemistryPyrazole COX inhibitors
researchProduct

Efficacy of intra-arterial lidocaine infusion in the treatment of cerulein-induced acute pancreatitis

2020

Background Disturbances in pancreatic microcirculation, beginning with vasoconstriction, are crucial in early pancreatitis and progression to necrotizing pancreatitis. Thus, vascular-targeted treatment aiming to restore a sufficient level of microcirculation through vasodilation would possibly reduce the severity of pancreatitis. Lidocaine is an anti-arrhythmic and local anesthetic drug, which also acts as a vasodilator at higher concentrations. Objectives To evaluate the efficacy of intra-arterial infusion of lidocaine into the celiac trunk in treatment of cerulein-induced acute pancreatitis. Material and methods Wistar rats (n = 20) were randomly divided into 2 equal groups: the control g…

Lidocaineacute pancreatitismedicine.drug_classMedicine (miscellaneous)microcirculationVasodilationLidocaine HydrochlorideGeneral Biochemistry Genetics and Molecular BiologyMicrocirculationRandom Allocationregional arterial infusionInternal MedicineMedicineAnimalsInfusions Intra-ArterialPharmacology (medical)Rats WistarPancreasGenetics (clinical)business.industryLocal anestheticmedicine.diseaseRatsTreatment OutcomePancreatitisAnesthesiaReviews and References (medical)Acute DiseaselidocainePancreatitisAcute pancreatitismedicine.symptombusinessVasoconstrictionCeruletidemedicine.drugAdvances in Clinical and Experimental Medicine
researchProduct

Volume and effectiveness assessment of articain 4% versus mepivacaine 2% used in third molar surgery : randomized, double-blind, split-mouth controll…

2020

Made available in DSpace on 2021-06-25T11:06:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-01-01 Background: The different indications for extraction of the lower third molars, require resources to manage pain and discomfort, such as, for example, adequate anesthetic techniques, and the type of anesthetic used can in-fluence the management of pain in tooth extractions. Few studies in the literature compare the anesthetics 4% articaine hydrochloride and 2% mepivacaine hydrochloride showing evidence that both allow for successful pain management. This study sought to compare the volume, efficacy and safety of these two anesthetic drugs, both associated with epinephrine at a ratio …

Local anaesthesiaVisual analogue scaleAnesthesia DentalMepivacainePainCarticaineArticaineArticaine Hydrochloridelaw.inventionCarticaineRandomized controlled trialDouble-Blind MethodlawThird molarmedicineHumansParesthesiaAnesthetics LocalGeneral Dentistrybusiness.industryResearch:CIENCIAS MÉDICAS [UNESCO]Clinical trialOtorhinolaryngologyAnesthesiaAnestheticMepivacaineTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryMolar ThirdOral Surgerybusinessmedicine.drug
researchProduct

Cold vapour atomic fluorescence determination of mercury in milk by slurry sampling using multicommutation

2004

Abstract A highly sensitive mechanized method has been developed for the determination of mercury in milk by atomic fluorescence spectrometry (AFS). Samples were sonicated for 10 min in an ultrasound water bath in the presence of 8% (v/v) aqua regia, 2% (v/v) antifoam A and 1% (m/v) hydroxilamine hydrochloride, and after that, they were treated with 8 mmol l −1 KBr and 1.6 mmol l −1 KBrO 3 in an hydrochloric medium. Atomic fluorescence measurements were made by multicommutation, which provides a fast alternative in quality control analysis, due to the easy treatment of a large number of samples (approximately 70 h −1 ), and is an environmentally friendly procedure, which involves a waste ge…

MERCUREDetection limitHydrochlorideAnalytical chemistrychemistry.chemical_elementBiochemistryAnalytical ChemistryMercury (element)Waste treatmentchemistry.chemical_compoundCertified reference materialschemistrySlurryEnvironmental ChemistryAqua regiaSpectroscopyAnalytica Chimica Acta
researchProduct

Design, synthesis and stimuli responsive gelation of novel stigmasterol-amino acid conjugates.

2020

Abstract An efficient synthesis of three novel stigmasterol-amino acid (glycine, l -leucine and l -phenylalanine) conjugates as stimuli responsive gelators is reported. The gelation properties of the prepared compounds were investigated in a variety of organic as well as aqueous solvents. The most striking finding of our investigation was that the hydrochloride salts of the prepared conjugates acted as gelators, whereas the neutral conjugates were either non-gelators or formed only a weak gel in anisole. The hydrochloride salts of stigmasteryl glycinate and l -leucinate form gels in n-alcohols (n = 4–10) and in ethane-1,2-diol, and that of stigmasteryl l -phenylalaninate forms gels in aroma…

Magnetic Resonance SpectroscopyHydrochloridePhenylalanineGlycineStigmasterolPhenylalaninePhase TransitionBiomaterialschemistry.chemical_compoundColloid and Surface ChemistryLeucineSpectroscopy Fourier Transform InfraredOrganic chemistrychemistry.chemical_classificationBiological ProductsAqueous solutionChemistryWaterHydrogen BondingHydrogen-Ion ConcentrationAnisoleSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsAmino acidDelayed-Action PreparationsGlycineSelf-healing hydrogelsMicroscopy Electron ScanningSolventsHydrochloric AcidLeucineGelsJournal of colloid and interface science
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

A standardization of the Novelty-Suppressed Feeding Test protocol in rats

2017

Tests based on hyponeophagia phenomena are the most widely used to check the efficacy and efficiency of new-generation chronic antidepressant treatments. Even so, these tests lack strict consensus about their methodology, which reduces their validity, reproducibility and makes translatability difficult. Therefore, after an extensive literature review on this subject, we propose a methodological protocol for the Novelty-Suppressed Feeding Test to normalize this situation. Animals were induced to a reserpine-induced depression model and were then chronically treated with duloxetine, desvenlafaxine or vehicle. After a 14-day treatment, a standardized Novelty-Suppressed Feeding Test was perform…

Male0301 basic medicineNormalization (statistics)medicine.medical_specialtyReserpineStandardizationDuloxetine HydrochlorideDuloxetine HydrochlorideRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysical medicine and rehabilitationmedicineAnimalsDuloxetinePsychiatryProtocol (science)Depressive DisorderDepressionGeneral NeuroscienceNoveltyReproducibility of ResultsAntidepressive AgentsTest (assessment)DesvenlafaxineDisease Models Animal030104 developmental biologychemistryExploratory BehaviorPsychology030217 neurology & neurosurgerymedicine.drugNeuroscience Letters
researchProduct

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic …

2016

[Purpose] TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.

Male0301 basic medicineOncologyCancer ResearchPyrrolidinesColorectal cancerTrifluridineHelsinki declarationlaw.inventionTrifluridinechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicineAged 80 and overMetastatic colorectal cancerPalliative CareHazard ratioGeneral MedicineMiddle AgedPrognosisTAS-102Survival RateDrug CombinationsOncology030220 oncology & carcinogenesisDrug Therapy CombinationFemaleColorectal NeoplasmsFluoropyrimidineResearch Articlemedicine.drugAdultmedicine.medical_specialtyanimal structuresSubgroup analysisPlaceboAntiviral Agents03 medical and health sciencesDouble-Blind MethodInternal medicineHumansTipiracil hydrochlorideUracilAgedNeoplasm StagingTipiracilbusiness.industrymedicine.diseaseSurgery030104 developmental biologychemistrySpainbusinessThymineFollow-Up StudiesClinical and Translational Oncology
researchProduct

Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells

2017

Several studies implicate that lung cancer progression is governed by the interaction between epidermal growth factor receptor (EGFR) signaling and protein kinase C (PKC) pathways. Combined the targeting of EGFR and PKC may have an additive or synergistic effects in lung cancer treatment. The aim of this study is to explore the potential utility by inhibiting these two pathways with the combination of erlotinib and chelerythrine chloride in non-small cell lung cancer (NSCLC) cell lines. The erlotinib-less sensitive cell lines SK-MES-1 and A549 were treated with erlotinib or chelerythrine by themselves or in combination with each other. The cell viability, clonogenic survival, cell migration…

Male0301 basic medicineOncologyCell signalingLung NeoplasmsCancer Treatmentlcsh:MedicineApoptosisMice SCIDSignal transductionLung and Intrathoracic TumorsMicechemistry.chemical_compoundMice Inbred NODCarcinoma Non-Small-Cell LungMedicine and Health SciencesEpidermal growth factor receptorPhosphorylationlcsh:ScienceErlotinib HydrochlorideMultidisciplinaryCell DeathbiologyPharmaceuticsChemistrySignaling cascadesFlow CytometryErbB ReceptorsCell MotilityOncologyCell ProcessesDrug Therapy CombinationErlotinibSignal transductionEGFR signalingResearch Articlemedicine.drugmedicine.medical_specialtyMAPK signaling cascadesCell MigrationErlotinib Hydrochloride03 medical and health sciencesDrug TherapyCell Line TumorInternal medicinemedicineAnimalsHumansViability assayLung cancerBenzophenanthridineslcsh:RCancers and NeoplasmsBiology and Life SciencesCell Biologymedicine.diseaseXenograft Model Antitumor AssaysNon-Small Cell Lung Cancerrespiratory tract diseases030104 developmental biologyChelerythrineApoptosisCancer researchbiology.proteinlcsh:QDevelopmental BiologyPLOS ONE
researchProduct

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with …

2016

// Giuseppe Bronte 1, * , Tindara Franchina 2, * , Massimiliano Alu 3, * , Giovanni Sortino 1 , Claudia Celesia 1 , Francesco Passiglia 1 , Giuseppina Savio 3 , Agata Laudani 3 , Alessandro Russo 2 , Antonio Picone 2 , Sergio Rizzo 1 , Michele De Tursi 4 , Elisabetta Gambale 4 , Viviana Bazan 1 , Clara Natoli 4 , Livio Blasi 3 , Vincenzo Adamo 2 , Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy 3 Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy 4 Department of Medical, Oral and Biotechnological …

Male0301 basic medicineOncologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classEGFRTyrosine kinase inhibitorKaplan-Meier EstimateTyrosine-kinase inhibitorErlotinib Hydrochloride03 medical and health sciences0302 clinical medicineGefitinibCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansChemotherapyErlotinib HydrochlorideLung cancerProtein Kinase InhibitorsChemotherapy EGFR Non-small-cell lung cancer Tyrosine kinase inhibitor OncologyAgedRetrospective StudiesAged 80 and overPerformance statusbusiness.industryChemotherapy; EGFR; Non-small-cell lung cancer; Tyrosine kinase inhibitor; OncologyGefitinibRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryErbB ReceptorsClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationQuinazolinesFemaleErlotinibbusinessNon-small-cell lung cancerResearch Papermedicine.drug
researchProduct